Biotech Values

[DewDiligence]

IDIX’s Board of Directors

[Updated for naming of Steven Projan as one of NVS’ two designates
on IDIX’s BoD. IDIX has nine directors: five independent, two named
by NVS, JP Sommadossi (founder and CEO), and one open slot. All
directors stand for reelection annually. Directors other than
Sommadossi are listed below in alphabetical order.]


Jean-Pierre Sommadossi, Ph.D., age 52; director since 1998:

Dr. Sommadossi is the principal founder of Idenix and has served as the chairman of our board of directors since our inception and as our president and chief executive officer since November 2000. During the period from November 1999 to November 2000, Dr. Sommadossi served as our executive president and chief scientific officer. Dr. Sommadossi served as a professor of pharmacology, toxicology and clinical pharmacology and associate director of both the Center for AIDS Research and the Liver Center, University of Alabama at Birmingham School of Medicine from June 1992 to November 2000. Dr. Sommadossi took a sabbatical and then unpaid leave from the University of Alabama from November 1999 to November 2002. From 1996 to 1999, Dr. Sommadossi served on the Research Agenda Committee of the AIDS Clinical Trial Group. Dr. Sommadossi holds a Pharm.D. and Ph.D. in Pharmacology from the University of Marseilles, France.


Charles W. Cramb, age 61; director since 2003:

Mr. Cramb has served as the executive vice president, finance, technology and chief financial officer of The Avon Company, a global beauty products company, since November 2005. Prior to joining The Avon Company, Mr. Cramb served as the chief financial officer at The Gillette Company, a worldwide consumer products company, from July 1997 to November 2005. From July 1995 to July 1997, Mr. Cramb served as a corporate vice president and corporate controller of The Gillette Company. He is also a member of the board of directors of Tenneco Automotive Inc. Mr. Cramb holds a B.A. from Dartmouth College and a M.B.A. from the University of Chicago.


Wayne T. Hockmeyer, Ph.D., age 63; director since 2002:

Dr. Hockmeyer founded MedImmune, Inc., a biotechnology company, in April 1988 and served until October 2000 as the chief executive officer of MedImmune. [MedImmune was acquired by AstraZeneca in 2007.] Dr. Hockmeyer also serves as a director of Advancis Pharmaceutical Corporation and GenVec, Inc. Dr. Hockmeyer was recognized, in 1998, by the University of Florida as a Distinguished Alumnus and in 2002 was awarded a Doctor of Science honoris causa from Purdue University. Dr. Hockmeyer holds a B.S. from Purdue University and a Ph.D. from the University of Florida.


Thomas R. Hodgson, age 66; director since 2002:

Mr. Hodgson, who is retired, served most recently, from September 1990 to January 1999, as president and chief operating officer of Abbott Laboratories, a diversified healthcare company. From 1983 to 1990, Mr. Hodgson served as the president of Abbott International and from 1978 to 1983, Mr. Hodgson served as the president of the Hospital Products Division of Abbott Laboratories. Mr. Hodgson is a director of The Travelers Companies Inc. Mr. Hodgson holds a B.S. from Purdue University, an M.S. from the University of Michigan, an M.B.A. from Harvard and an honorary doctorate degree in engineering awarded by Purdue University.


Robert E. Pelzer, age 53; director since 2003:

Mr. Pelzer is general counsel of Novartis’ US subsidiary and is one of the two directors designated by NVS. Prior to his appointment at Novartis in March 2002, Mr. Pelzer was general counsel at DuPont Pharmaceuticals Company from 1998 to December 2001. Prior to that time, Mr. Pelzer held various positions with The DuPont Company. Mr. Pelzer holds degrees in Commerce and in Law from the University of Alberta. He is admitted as barrister and solicitor in the Province of Alberta, Canada, and as Solicitor in England and Wales.


Denise Pollard-Knight, Ph.D., age 48; director since 2003:

Dr. Pollard-Knight has served since April 2004 as head of Nomura Phase4 Ventures, an affiliate of Nomura International plc, a leading Japanese financial institution. From January 1999 to March 2004, Dr. Pollard-Knight served as head of Healthcare Private Equity at Nomura International plc. From January 1997 to January 1999, Dr. Pollard-Knight was a member of Rothschild Asset Management Ltd., an investment management firm. Dr. Pollard-Knight holds a Ph.D. and BSc (Hons) from the University of Birmingham in England. Dr. Pollard-Knight completed post-doctorate work as a Fulbright Scholar at the University of California, Berkeley.


Steven Projan, Ph.D., age unknown; director since Feb 2009:

Dr. Projan is the head of NVS’ R&D team in infectious diseases and is one of the two directors designated by NVS.


Pamela Thomas-Graham, age 44; director since 2005:

Ms. Thomas-Graham has served as group president overseeing men’s and women’s apparel for better, moderate and mid-tier department stores for Liz Claiborne, Inc., an apparel and retail company, since October 2005. Prior to joining Liz Claiborne, Inc., Ms. Thomas-Graham served most recently as chairman of CNBC from February 2005 to October 2005 and served as president and chief executive officer of CNBC from July 2001 to February 2005. From February 2001 to July 2001, Ms. Thomas-Graham served as president and chief operating officer of CNBC. From September 1999 to February 2001, Ms. Thomas-Graham served as an executive vice president of NBC, and president and chief executive officer of CNBC.com. Prior to joining NBC, Ms. Thomas-Graham was a partner at McKinsey & Company from December 1995 to September 1999. Ms. Thomas-Graham also serves as a director of the Clorox Company. Ms. Thomas-Graham holds a J.D., M.B.A. and B.A. from Harvard University.